Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms.
Recombinant human interleukin-4 (rhIL-4) has pleiotropic biologic effects including stimulation of normal B-cell growth. We investigated the effects of rhIL-4 on the in vitro growth of 35 fresh human lymphoid and plasma cell malignancies. Inhibition of growth was seen in 52% and 60% of multiple myeloma and lymphoma specimens, respectively. Growth was stimulated relative to control in 8.6% (3 of 35) of the tumors tested. Immunophenotyping showed that tumors displaying growth stimulation expressed surface markers associated with a poor clinical prognosis. Our findings support the clinical evaluation of rhIL-4 as a therapeutic agent in selected patients with lymphoid and plasma cell neoplasms.
Taylor
C W
CW
Department of Internal Medicine, University of Arizona College of Medicine, Tucson 85724.
Grogan
T M
TM
Salmon
S E
SE
D000951:Antigens, Neoplasm / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D015847:Interleukin-4 / Q000494:pharmacology*; D008223:Lymphoma / Q000276:immunology / Q000473:pathology*; D009101:Multiple Myeloma / Q000473:pathology*; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D011994:Recombinant Proteins; D015847:Interleukin-4